Nanoengineered polymers and other organic materials in lung cancer treatment: Bridging the gap between research and clinical applications

Xuru Jin, Golnaz Heidari, Zhidan Hua, Ying Lei, Jinfeng Huang, Zixiang Wu, Ana Cláudia Paiva-Santos, Zhanhu Guo, Hassan Karimi Male, Rasoul Esmaeely Neisiany*, Mika Sillanpää, Chander Prakash, Xiangdong Wang, Ying Tan, Pooyan Makvandi, Yi Xu

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

5 Downloads (Pure)


Cancer remains a major global health challenge, with increasing incidence and mortality rates projected for the coming years. Lung cancer, in particular, poses significant obstacles due to late-stage diagnosis and limited treatment options. While advancements in molecular diagnostics have been made, there is a critical need to connect the dots between laboratory and hospital for better lung cancer treatment. Systemic therapy plays a crucial role in treating advanced-stage lung cancer, and recent efforts have focused on developing innovative drug delivery techniques. Nanoparticles (NPs) have emerged as a promising approach to lung cancer treatment, offering enhanced drug delivery, active targeting, and reduced toxicity. Organic-based nanomaterials, like polymeric nanoparticles, solid lipid nanoparticles, and liposomes hold great potential in this field. This review examines the application of NPs in lung cancer treatment, highlights current therapies, explores organic nanoparticle-based approaches, and discusses limitations and future perspectives in clinical translation.

Original languageEnglish
Article number112891
Pages (from-to)1-11
Number of pages11
JournalEuropean Polymer Journal
Early online date27 Feb 2024
Publication statusPublished - 25 Mar 2024

Cite this